>

Bharat Biotech’s nasal vaccine gets the Government nod

Share

The intranasal vaccine against coronavirus being developed by Bharat Biotech and supported by Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) has got the regulator nod for Phase 2-3 trials.

 

Bharat Biotech‘s intranasal vaccine is the first nasal vaccine in the country that has received the regulatory approval for Phase 2/3 trials, the Ministry of Science and Technology said in a statement.

 

This is the first of its kind Covid-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis, USA,” it said.

 

The phase 1 clinical trial of the vaccine has been completed in age groups ranging 18-60 years. The Company reported that the doses of the vaccine administered to healthy volunteers in the Phase I clinical trial, has been well tolerated. No serious adverse events reported.

 

Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level of neutralizing antibodies in animal studies.

 

The regulatory approval has been received for conducting “a Phase 2 randomised, multi-centric, clinical trial of heterologus prime-boost combination of SARS-CoV-2 vaccines to evaluate the immunogenicity and safety of BBV152 (COVAXIN®) with BBV154 (Adenoviral Intranasal Covid-19 vaccine) in Healthy Volunteers.”

 

Dr RenuSwarup, Secretary, DBT and Chairperson, BIRAC speaking on the subject said that “the Department through mission Covid Suraksha, is committed to development of safe and efficacious Covid-19 vaccines.

 

Mission COVID Suraksha was launched to reinforce and accelerate COVID-19 vaccine development efforts as part of the third stimulus package, Atmanirbhar 3.0, the PIB release said. Its focus is to consolidate and streamline available resources towards accelerated vaccine development.

Share